论文部分内容阅读
头孢噻肟为第三代头孢菌素,在体外具有抗奈瑟氏淋球菌作用,单剂量肌注Ig通常有效,已被疾病控制中心推荐作为治疗无合并症淋病的替代方案。作者进行了一项随机多中心研究,通过与头孢三嗪250mg肌注比较,来评估头孢噻肟500mg肌注治疗无合并症淋病的有效性和安全性。受试病人需符合下列条件:①有1份取自任何部位的淋球菌培养阳性结果;②尿道或宫颈涂片革兰染色可见白细胞和细胞内革兰阴性双球菌;③女性患者近期与已确诊尿道淋病男性患者有性接触。若近期曾应用过丙磺舒或其它具有抗淋球菌作用的抗生素、研
Cefotaxime, the third generation cephalosporin, has an anti-Neisseria gonorrhoeae effect in vitro. A single dose of intramuscular injection of Ig is usually effective and has been recommended by the Centers for Disease Control and Prevention as an alternative to the treatment of non-comorbid gonorrhea. The authors conducted a randomized multicenter study to evaluate the efficacy and safety of cefotaxime 500 mg intramuscular injection in the treatment of non-comorbid gonorrhea compared with intramuscular injection of ceftriaxone 250 mg. Patients should meet the following conditions: ① 1 from any part of the gonococcal culture positive results; ② urethra or cervical smear Gram-stain visible white blood cells and intracellular gram-negative bacteria; ③ female patients recently diagnosed Urinary tract gonorrhea male patients have sexual contact. If the recent application of probenecid or other anti-gonococcal antibiotics, research